At the Radiotherapy Unit of HC Cancer Center, we keep advancing in the incorporation of innovative oncological treatments that contribute to improve the survival and quality of life of our patients. One of the latest advances we have incorporated is Optune Gio, a portable and non-invasive medical device based on Tumour Treating Fields (TTFields) technology, indicated for the treatment of grade 4 glioma.
This technology is a therapeutic alternative that complements conventional treatments, offering another option for patients diagnosed with this type of aggressive brain tumour.
Optune Gio acts directly on tumour cells by emitting low-intensity electric fields through patches placed on the scalp. These fields interrupt cancer cell’s ability to divide, preventing them from multiplying, without damaging the surrounding healthy tissue.
Treatment is continuous and the device can be used at home, thus allowing patients to maintain a relatively normal daily routine, without the need for hospitalisation.
This device is indicated for adult patients with newly diagnosed grade 4 glioma and can be used in the following scenarios:
- After resection surgery or biopsy of the tumour
- After radiotherapy treatment
- In combination with Temozolomide (with or without Lomustine) as maintenance treatment
- At the end of systemic therapy
The goal is to slow tumour growth and improve survival after completing the initial phases of treatment.
- It improves the overall survival of patients.
- It prolongs the time patients do not experience tumour progression.
- It is non-invasive, painless and does not require hospitalisation.
- It is compatible with other treatments such as chemotherapy.
- It allows patients to lead an active life and maintain their autonomy.
- Low level of adverse effects; the most common is mild skin irritation.
- Mejora la supervivencia global de los pacientes.
The efficacy of Optune Gio has been supported by numerous clinical studies. The most relevant of these is the EF-14 trial, in which it was observed that:
- Median overall survival increased from 16 to 20.9 months.
- The 5-year survival rate doubled (from 5% to 13%) in patients treated with Optune Gio and Temozolomide.
- There was a significant improvement in the quality of life related to overall health and cognitive function of the patients.
- La supervivencia media global aumentó de 16 a 20,9 meses.
This treatment is recommended by international guidelines such as those of the National Comprehensive Cancer Network (NCCN) and is CE marked (CE-0197) for use in Europe.
At HC Marbella we offer a multidisciplinary approach, with a team of specialists in oncology, radiotherapy and neurosurgery who study each case in a personalised way. Our priority is to offer the best therapeutic options available, combining efficacy, safety and quality of life.
If you or a loved one has been diagnosed with a grade 4 glioma, please consult us. We will be there to help you evaluate all the possible alternatives, including treatment with Optune Gio.
Scientific references
1. Stupp R. et al. (2017). JAMA, 318(23):2306–2316.
2. Stupp R. et al. (2021). JAMA Oncology.
3. NCCN Guidelines – Central Nervous System Cancers.
4. Novocure: Documentación clínica de Optune Gio.
Dra. Cristina Nuño
Radiation Oncology Specialist
June 13, 2025
Read other news
Tel.: +34 952 908 628
+34 609 148 799
952908898 Oncology
951829978 Diagnosis by imaging
951829947 Gynecology
952908897 Fertility
951829947 Physiotherapy
